ECE2015 Eposter Presentations Diabetes (complications & therapy) (143 abstracts)
Once-weekly exenatide in a real-world clinical setting: clinical outcomes and analysis of potential predictors of response
María del Mar Roca-Rodriguez 1 , Jose Carlos Fernandez-Garcia 1 , Carmen Maria Cortes-Salazar 2 , Isabel Moya-Carmona 3 , Ana María Gomez-Perez 1 , Isabel Cornejo-Pareja 1 , Araceli Muñoz-Garach 1 , Maria Molina-Vega 1 , Isabel Mancha Doblas 1 & Francisco Tinahones 1
1Endocrinology Department, Virgen de la Victoria University Hospital, Malaga, Spain; 2Badolatosa Primary Care Centre, Seville, Spain; 3Pharmacy Department, Virgen de la Victoria University Hospital, Malaga, Spain.
Objective: The aim of this study is to evaluate the effectiveness of once-weekly exenatide on metabolic control, weight, blood pressure, and lipid profile in obese patients with type 2 diabetes (T2DM), and to assess possible predictive factors of response.
Material and methods: Retrospective observational study, conducted with adult obese (BMI ≥30 kg/m2) T2DM subjects that had been initiated once-weekly exenatide following routine clinical practice. Anthropometric measures, blood analysis, and blood pressure measures were collected at the initiation of once-weekly exenatide (V0) and after 16±4 weeks of treatment (V1). Predictors of target metabolic response (HbA1c <7%), were evaluated by using a multiple logistic model.
Results: 31 patients were included (mean age 54.4±10.7 years; female 54.8%; and mean duration of T2DM 7.9±5.4 years). Significant changes from V0 to V1 were observed in weight-related parameters (body weight 108.1±28.8 kg vs 101.3±22.3 kg and BMI 41.2±8 kg/m2 vs 39.3±7.3 kg/m2, P<0.001 for both); HbA1c (8.6±1.6% vs 7.3±1.3%, P<0.001), lipid profile (total cholesterol 206.4±37 mg/dl vs 181±41.5 mg/dl, P=0.002; LDL-cholesterol 124.3±35.8 mg/dl vs 101.6±39.2 mg/dl, P=0.003; HDL-cholesterol 39.4±10.7 vs 40.7±10.3, P=0.331; and triglycerides 288.1±125.7 mg/dl vs 195.1±80 mg/dl, P=0.001). No differences in blood pressure (systolic or diastolic) or number of antihypertensive drugs were found. 45.2% of patients achieved HbA1c <7%, 64.5% lost weight, and 41.9% simultaneously achieved HbA1c <7% and lost weight. None of the studied variables (age, sex, duration of diabetes, baseline HbA1c, and BMI) were confirmed as predictors of response.
Conclusions: In obese patients with T2DM, once-weekly exenatide increases metabolic control, decreases body weight, and improves lipid profile. However, once-weekly exenatide does not exert beneficial effects on blood pressure. Age, sex, duration of diabetes, baseline HbA1c, and BMI were not predictors of efficacy of once-weekly exenatide.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more